<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127319</url>
  </required_header>
  <id_info>
    <org_study_id>AHHU-2017AMZ01</org_study_id>
    <nct_id>NCT03127319</nct_id>
  </id_info>
  <brief_title>A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases</brief_title>
  <official_title>A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Hospital of Hebei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Hospital of Hebei University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of patients who receive
      apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line
      treatment for advanced non-squamous non-small cell lung cancer with bone metastases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR (Disease control rate)</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (Objective response rate)</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SREs（Skeletal-related events）</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
    <description>measured pain, a fracture, the need for bone radiation or surgical therapy, spinal cord compression, or hypercalcemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-squamous Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>apatinib and docetaxel zoledronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv&gt;15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel zoledronic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel 60mg/m² iv q3w;zoledronic 4mg iv&gt;15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib docetaxel zoledronic</intervention_name>
    <description>apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv&gt;15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>apatinib and docetaxel zoledronic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel zoledronic</intervention_name>
    <description>docetaxel 60mg/m² iv q3w;zoledronic 4mg iv&gt;15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>docetaxel zoledronic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18 to 75 years old (man or female)

          2. Pathologically diagnosed with metastatic or recurrent non-squamous non-small cell lung
             cancer

          3. Patients with at least one evaluate lesions of the lung and bone
             metastases.(measuring≥10mm on spiral CT scan, satisfying the criteria in RECIST1.1 and
             WHO)

          4. Refractory or failure of prior therapy

          5. Life expectancy greater than or equal to 3 months

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          7. Major organ function has to meet the following criteria:

               -  For results of blood routine test (without blood transfusion within 14 days)

                    1. HB≥90g/L

                    2. ANC≥1.5×109/L

                    3. PLT≥180×109/L

               -  For results of blood biochemical test：

                    1. TBIL&lt;1.5×ULN；

                    2. ALT and AST&lt;2.5×ULN, but&lt; 5×ULN if the transferase elevation is due to liver
                       metastases；

                    3. Serum creatinine ≤1.25×ULN , or calculated creatinine clearance＞45
                       ml/min(per the Cockcroft-Gault formula);

          8. Women of childbearing age must have contraceptive measures or have test pregnancy
             (serum or urine) enroll the study before 7 days, and the results must be negative, and
             take the methods of contraception during the test and the last to have drugs after 8
             weeks. Men must be contraception or has sterilization surgery during the test and the
             last to have drugs after 8 weeks;

          9. Participants were willing to join in this study, and written informed consent, good
             adherence, cooperate with the follow-up.

        Exclusion Criteria:

          1. Allergic to apatinib and docetaxel;

          2. Have high blood pressure and antihypertensive drug treatment can not control (systolic
             blood pressure &gt; 140 mmHg, diastolic blood pressure &gt; 90 mmHg), with class Ⅱ and above
             coronary heart disease, arrhythmia (including QTc lengthened men &gt; 450 ms, women &gt; 470
             ms) and class Ⅲ-Ⅳ cardiac insufficiency;

          3. A variety of factors influencing oral drugs (such as unable to swallow, nausea,
             vomiting, chronic diarrhea and intestinal obstruction, etc.).

          4. Patients with tendency of gastrointestinal bleeding, including the following: a local
             active ulcerative lesions, and defecate occult blood (+ +); Has melena and hematemesis
             in two months; For defecate occult blood (+) and primary lesions without surgical
             removal of the stomach tumor, requirement of gastroscopy, such as ulcer type of
             gastric cancer, and researchers think that may be gastrointestinal hemorrhage;

          5. Coagulant function abnormality (INR &gt; 1.5 ULN, APTT &gt; 1.5 ULN), with bleeding
             tendency.

          6. Patients with symptoms of central nervous system metastasis.

          7. Pregnant or lactating women.

          8. history of psychiatric drugs abuse and can't quit or patients with mental disorders.

          9. Less than 4 weeks from the last clinical trial.

         10. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aimin Zang</last_name>
    <phone>13930881628</phone>
    <email>15175292891@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei university</name>
      <address>
        <city>BaoDing</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Zang</last_name>
      <phone>13930881628</phone>
      <email>15175292891@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Hospital of Hebei University</investigator_affiliation>
    <investigator_full_name>Aimin Zang</investigator_full_name>
    <investigator_title>Director of oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

